Clinical Trials Logo

Refractory Glioblastoma clinical trials

View clinical trials related to Refractory Glioblastoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04385173 Recruiting - Clinical trials for Recurrent Glioblastoma

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

NCT ID: NCT04077866 Recruiting - Clinical trials for Recurrent Glioblastoma

B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

NCT ID: NCT04003649 Recruiting - Clinical trials for Recurrent Glioblastoma

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Start date: December 2, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms that may attack specific glioma cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving IL13Ralpha2-CAR T cells and nivolumab together may work better in treating patients with glioblastoma.